Product Description
Fosfomycin is a bactericidal antibiotic agent. It inhibits an enzyme-catalyzed reaction in the first step of the synthesis of the bacterial cell wall (9). Fosfomycin interferes with the first cytoplasmic step of bacterial cell wall biosynthesis, the formation of the peptidoglycan precursor UDP N-acetylmuramic acid (UDP-MurNAc) (Sourced from: https://journals.asm.org/doi/10.1128/CMR.00068-15)
Mechanisms of Action: FOSA Agonist,Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Cardeas Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Denmark, France, Mexico, Spain, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Febrile Neutropenia|Urinary Tract Infections
Phase 2: Adenoma|Bladder Cancer|Colorectal Cancer|Pouchitis|Urologic Cancer
Phase 1: Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024-517764-38-00 | P2 |
Unknown Status |
Pouchitis |
2027-08-02 |
|
| 2021/0376/HP | P3 |
Unknown Status |
Urinary Tract Infections |
2027-06-01 |
|
| Pediatric_PK | P1 |
Recruiting |
Other |
2025-12-31 |
21% |
| FOVOCIP | P3 |
Recruiting |
Febrile Neutropenia |
2024-03-14 |